癌症研究
上皮-间质转换
甲状腺癌
甲状腺乳突癌
转移
波形蛋白
癌症
肿瘤进展
染色质免疫沉淀
生物
医学
内科学
基因表达
基因
免疫组织化学
生物化学
发起人
作者
Gaoda Ju,Tao Xing,Miaomiao Xu,Xin Zhang,Yuqing Sun,Zhuanzhuan Mu,Di Sun,Sen Miao,Li Li,Jun Liang,Yansong Lin
出处
期刊:Neoplasia
[Elsevier]
日期:2024-03-01
卷期号:49: 100972-100972
标识
DOI:10.1016/j.neo.2024.100972
摘要
Papillary thyroid cancer (PTC) is the most prevalent endocrine cancer worldwide. Approximately 30 % of PTC patients will progress into the advanced or metastatic stage and have a relatively poor prognosis. It is well known that epithelial-mesenchymal transition (EMT) plays a pivotal role in thyroid cancer metastasis, resistance to therapy, and recurrence. Clarifying the molecular mechanisms of EMT in PTC progression will help develop the targeted therapy of PTC. The aberrant expression of some transcription factors (TFs) participated in many pathological processes of cancers including EMT. In this study, by performing bioinformatics analysis, adipocyte enhancer-binding protein 1 (AEBP1) was screened as a pivotal TF that promoted EMT and tumor progression in PTC. In vitro experiments indicated that knockout of AEBP1 can inhibit the growth and invasion of PTC cells and reduce the expression of EMT markers including N-cadherin, TWIST1, and ZEB2. In the xenograft model, knockout of AEBP1 inhibited the growth and lung metastasis of PTC cells. By performing RNA-sequencing, dual-luciferase reporter assay, and chromatin immunoprecipitation assay, Bone morphogenetic protein 4 (BMP4) was identified as a downstream target of AEBP1. Over-expression of BMP4 can rescue the inhibitory effects of AEBP1 knockout on the growth, invasion, and EMT phenotype of PTC cells. In conclusion, these findings demonstrated that AEBP1 plays a critical role in PTC progression by regulating BMP4 expression and the AEBP1-BMP4 axis may present novel therapeutic targets for PTC treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI